Multi-center Study to Transplant Hepatitis-C Infected Kidneys

Phase 4 Completed 30 enrolled Raymond Chung AbbVie · collab Johns Hopkins University · collab Northwestern University · collab University of Cincinnati · collab University of Michigan · collab University of Pennsylvania · collab Weill Medical College of Cornell University · collab

NaSingle-groupOpen-labelPrevention

Summary

Open label multi center study for the donation of HCV positive kidneys to HCV negative recipients with interventional treatment to prevent HCV transmission upon transplantation.

Timeline

Start: 2019-04-10
Primary completion: 2020-03-20
Completion: 2021-12-31

Publications

Sise ME, Goldberg DS, Schaubel DE, Fontana RJ, Kort JJ, Alloway RR, Durand CM, Blumberg EA, Woodle ES, Sherman KE, Brown RS Jr, Friedewald JJ, Desai NM, Sultan ST, Levitsky J, Lee MD, Strohbehn IA, Landis JR, Fernando M, Gustafson JL, Chung RT, Reese PP. One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) Trial. Kidney Int Rep. 2021 Dec 1;7(2):241-250. doi: 10.1016/j.ekir.2021.11.022. eCollection 2022 Feb.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	glecaprevir/pibrentasvir	Unknown	—	—

Multi-center Study to Transplant Hepatitis-C Infected Kidneys

Summary

Timeline

Publications

Drugs

Indications